Genentech, a member of the Roche Group (SIX:RO,ROG;OTCQX:RHHBY), announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval to Venclexta (venetoclax), in combination with a hypomethylating agent (azacitidine or decitabine), or low-dose cytarabine (LDAC), for the treatment of people with newly-diagnosed acute myeloid leukemia (AML), who are age 75 years or older, or … Continued
The post Genentech Announces FDA Grants Venclexta Accelerated Approval appeared first on Investing News Network.
Original Article: Genentech Announces FDA Grants Venclexta Accelerated Approval